Get the Stockscreener App
1.09
5.47%
-0.19
Trevena Inc stock is traded at $1.09, with a volume of 2,806.
It is down -5.47% in the last 24 hours and down -60.53% over the past month.
See More
Previous Close:
$1.28
Open:
$1.2
24h Volume:
2,806
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
$3.13M
Net Income/Loss:
$-40.29M
P/E Ratio:
-0.3406
EPS:
-3.2
Net Cash Flow:
$-33.08M
1W Performance:
-5.47%
1M Performance:
-60.53%
6M Performance:
+427.32%
1Y Performance:
+221.67%
1-Day Range:
$0.988
$1.23
1-Week Range:
$0.988
$1.23
52-Week Range:
$0.988
$1.23
Trevena Inc Stock (TRVN) Company Profile
Compare TRVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVN
Trevena Inc
|
1.09 | 0 | 3.13M | -40.29M | -33.08M | -3.20 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Trevena Inc Stock (TRVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-21 | Initiated | Oppenheimer | Perform |
| Sep-14-20 | Initiated | Guggenheim | Buy |
| Aug-28-20 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-19 | Resumed | H.C. Wainwright | Buy |
| Nov-05-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-12-18 | Downgrade | Needham | Buy → Hold |
| Oct-10-18 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-17 | Reiterated | Needham | Buy |
| Oct-16-17 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-12-17 | Reiterated | H.C. Wainwright | Buy |
| May-08-17 | Reiterated | Needham | Buy |
| Feb-23-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Reiterated | FBR & Co. | Outperform |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-09-17 | Initiated | H.C. Wainwright | Buy |
| Jan-05-17 | Initiated | Oppenheimer | Outperform |
| May-17-16 | Reiterated | FBR Capital | Outperform |
| May-17-16 | Reiterated | Needham | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
| Sep-01-15 | Reiterated | Wedbush | Outperform |
| Aug-03-15 | Initiated | Brean Capital | Buy |
View All
Trevena Inc Stock (TRVN) Latest News
COVID-19 Therapeutics Market Current Scenario with Future Aspect Analysis - openPR.com
Opioid Drugs Market: Investment Analysis & Growth Opportunity - openPR.com
Highest-Paid CEOs2024 - AFL-CIO
Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com - Defense World
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aviation Co. Says Workers' Class Action Too Broad - Law360
Block & Leviton Reminds Shareholders of Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN) - Defense World
Trevena (NASDAQ:TRVN) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Opioid Drugs Market Detailed In New Research Report 2025-2032 | - openPR.com
Trevena Delays Yearly Report Filing - TipRanks
Trevena (TRVN) Expected to Announce Quarterly Earnings on Monday - Defense World
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V - The Manila Times
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times
Global Post Operative Pain Management Market Advancements Highlighted by Forecast: Key Growth Drivers, Tren... - WhaTech
Ten option delistings on March 24th - TipRanks
Trevena (NASDAQ:TRVN) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN) - The AM Reporter
Opioid Drugs Market to Witness Remarkable Growth with Johnson & Johnson, Endo International plc - openPR
Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com - Defense World
Trevena, Inc. to Host Earnings Call - ACCESS Newswire
Trevena (NASDAQ:TRVN) Now Covered by StockNews.com - Defense World
Opioid Drugs Market Growth, Demand Trends, Size & Competitive - openPR
Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com - Defense World
Promising Automotive Stocks To Keep An Eye On – February 04th - ETF Daily News
Trevena Announces Board and Executive ChangesOn January 31, 2025, Trevena, Inc. (NASDAQ:TRVN) filed a Form 8-K with the Securities and Exchange Commission, detailing significant departures and appointments within the company.In line with ongoin - Defense World
Trevena Implements Cost-Cutting Measures Amid Leadership Changes - TipRanks
Trevena (NASDAQ:TRVN) Shares Cross Below 200 Day Moving Average – Time to Sell? - Defense World
Trevena discontinues OLINVYK injection sales By Investing.com - Investing.com Canada
Trevena discontinues OLINVYK injection sales - Investing.com
Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com - Defense World
Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection - Reuters.com
Trevena Announces Reverse Stock Split to Regain Nasdaq Compliance - MSN
With a 1.8% CAGR, the Opioid Market is Expected to Reach USD 28.45 billion by 2034 | PMR - GlobeNewswire
Trevena's SWOT analysis: CNS drug developer's stock faces pivotal moment - Investing.com
Trevena Inc Stock (TRVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
1.09%
Cap:
|
Volume (24h):